Intravenous cis‐platinum for invasive bladder cancer
Intravenous cis‐platinum for invasive bladder cancer
复制标题
静脉注射顺铂治疗浸润性膀胱癌
DOI：
--
复制
发表时间：
1984
影响因子：
11.4
通讯作者：
W. Woods
中科院分区：
文献类型：
--
作者：
D. Raghavan;B. Pearson;G. Coorey;D. Arnold;John Smith;J. Donovan;P. Langdon;W. Woods
无论给予何种治疗，局部浸润性膀胱癌（T3 - T4期、Nx期、Mo期）患者的5年生存率均低于50%。为了改善该疾病患者的预后，我们在手术或放疗（作为“最终”治疗）前将顺铂静脉注射两个周期纳入管理方案。在最初接受治疗的12名患者中，有10名患者在组织学上证实了肿瘤坏死，8名患者在接受顺铂治疗两个周期后出现了明确的临床反应。毒性是可以接受的，后续的管理也没有受到损害。
The five‐year survival rate of patients with locally invasive bladder cancer (stages T3‐T4, Nx, Mo) is less than 50% whatever treatment is given. In an effort to improve the prognosis of patients with this disease, we have incorporated into a management protocol two cycles of intravenous administration of cis‐platinum before surgery or radiotherapy (which function as the “definitive” treatment). In 10 of the first 12 patients treated, tumour necrosis has been demonstrated histologically, and definite clinical responses have been observed in eight patients after two cycles of cis‐platinum treatment. The toxicity has been acceptable, and subsequent management has not been compromised.